Bactolife, a Copenhagen-based company developing Binding Protein technology for gut health, raised over €30 million in a Series B round to fund large-scale human studies, scale manufacturing, and support global market entry, with the first product launch planned in the US in 2026.
With €30M+ Series B, Danish Bactolife Prepares Shift From R&D to Commercial Scale
January 8, 2026